Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Liver Diseases

  Free Subscription

Articles published in Anticancer Res

Retrieve available abstracts of 258 articles:
HTML format

Single Articles

    July 2021
  1. KUBO H, Ikoma H, Yamamoto Y, Morimura R, et al
    Therapeutic Strategy of Colorectal Liver Metastasis Using Modified-JHBPS Nomogram.
    Anticancer Res. 2021;41:3657-3665.
    PubMed     Abstract available

  2. VIEIRA JF, Peixoto AP, Murta EFC, Michelin MA, et al
    Prophylactic Dendritic Cell Vaccination in Experimental Breast Cancer Controls Immunity and Hepatic Metastases.
    Anticancer Res. 2021;41:3419-3427.
    PubMed     Abstract available

    June 2021
  3. AU KY, Chan KK, Lo RC
    A Clinicopathological Study of Young-onset Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:2933-2944.
    PubMed     Abstract available

    May 2021
  4. YAMAMURA K, Beppu T, Oda E, Sato N, et al
    Hepatic Inflammatory Pseudotumor Mimicking Malignant Tumor With Rare Onset of Intra-abdominal Hemorrhage.
    Anticancer Res. 2021;41:2727-2732.
    PubMed     Abstract available

  5. KIM HC, Choi JW, Lee M, Kim YJ, et al
    Yttrium-90 Radioembolization for Hepatocellular Carcinoma: Virtual Tumor Absorbed Dose as a Predictor of Complete Response.
    Anticancer Res. 2021;41:2625-2635.
    PubMed     Abstract available

  6. YAMAMOTO T, Imai N, Yamamoto K, Ito T, et al
    Tolerability of Molecular-targeted Agents for Hepatocellular Carcinoma Treatment in Haemophiliacs.
    Anticancer Res. 2021;41:2569-2573.
    PubMed     Abstract available

  7. ISHIGAMI I, Shuwari N, Kaminade T, Mizuguchi H, et al
    A TGFbeta Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFbeta-independent Manner.
    Anticancer Res. 2021;41:2431-2440.
    PubMed     Abstract available

  8. SHIBUTANI M, Kimura K, Kashiwagi S, Wang EN, et al
    Elevated Postoperative Levels of Serum C-reactive Protein Are Associated With Shorter Long-term Survival After Resection of Colorectal Liver Metastases, Regardless of the Occurrence of Infectious Complications.
    Anticancer Res. 2021;41:2605-2610.
    PubMed     Abstract available

  9. NISHIKAWA H, Fukunishi S, Asai A, Nishiguchi S, et al
    Obesity and Liver Cancer in Japan: A Comprehensive Review.
    Anticancer Res. 2021;41:2227-2237.
    PubMed     Abstract available

    April 2021
  10. MAESAKA K, Sakamori R, Yamada R, Tahata Y, et al
    Efficacy of Ramucirumab Versus Sorafenib as Subsequent Treatment for Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:2187-2192.
    PubMed     Abstract available

  11. FURUKAWA K, Haruki K, Yasuda J, Onda S, et al
    Strategies to Perform Curative Laparoscopic Repeat Hepatectomy for Recurrent Liver Tumors After Open Right Lobectomy.
    Anticancer Res. 2021;41:2171-2175.
    PubMed     Abstract available

  12. SASAKI R, Fukushima M, Haraguchi M, Miuma S, et al
    Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.
    Anticancer Res. 2021;41:2025-2032.
    PubMed     Abstract available

  13. SHAO C, Shao PP, Chen WT, Lin CC, et al
    Direct-acting Antiviral Therapy Improves the Outcome of Chronic Hepatitis C/intermediate-stage B Hepatocellular Carcinoma Patients.
    Anticancer Res. 2021;41:2007-2016.
    PubMed     Abstract available

  14. YASUHARA Y, Komatsu S, Kuramitsu K, Kido M, et al
    Feasibility of Reductive Hepatectomy in Patients With BCLC B and C Hepatocellular Carcinoma.
    Anticancer Res. 2021;41:1975-1983.
    PubMed     Abstract available

  15. LEE GW, Hur W, Kim JH, Park DJ, et al
    Nardostachys jatamansi Root Extract Attenuates Tumor Progression in Hepatocellular Carcinoma via Inhibition of ERK/STAT3 Pathways.
    Anticancer Res. 2021;41:1883-1893.
    PubMed     Abstract available

  16. NISHINO H, Okuno M, Seo S, Toda R, et al
    Sinusoidal Obstruction Syndrome Promotes Liver Metastatic Seeding of Colorectal Cancer Cells in a Rat Model.
    Anticancer Res. 2021;41:1803-1810.
    PubMed     Abstract available

  17. SHIBA S, Shibuya K, Okamoto M, Okano N, et al
    Carbon-ion Radiotherapy for Oligometastatic Colorectal Cancer in the Liver or Lung.
    Anticancer Res. 2021;41:1997-2005.
    PubMed     Abstract available

    March 2021
  18. PERL RM, Portugall J, Hinterleitner C, Hinterleitner M, et al
    Differences Between CT-Perfusion and Biphasic Contrast-enhanced CT for Detection and Characterization of Hepatocellular Carcinoma: Potential Explanations for Discrepant Cases.
    Anticancer Res. 2021;41:1451-1458.
    PubMed     Abstract available

  19. PARK SY, Seo YR, Ko MJ, Lee JH, et al
    Targeting CALM2 Inhibits Hepatocellular Carcinoma Growth and Metastasis by Suppressing E2F5-mediated Cell Cycle Progression.
    Anticancer Res. 2021;41:1315-1325.
    PubMed     Abstract available

  20. AKIBA J, Yoshida T, Sadashima E, Murata K, et al
    The Expression of PEDF and its Putative Receptors in Hepatocellular Carcinoma and Background Liver Tissue.
    Anticancer Res. 2021;41:1203-1212.
    PubMed     Abstract available

  21. NAKANISHI Y, Hirota S, Hojo Y, Nakamura T, et al
    Pathological Complete Remission of Liver Metastases Correlates With Elimination of Tumor-infiltrating Tregs in Gastric Cancer.
    Anticancer Res. 2021;41:1571-1577.
    PubMed     Abstract available

  22. HIROSE Y, Sakata J, Kobayashi T, Miura K, et al
    NQO1 as a Marker of Chemosensitivity and Prognosis for Colorectal Liver Metastasis.
    Anticancer Res. 2021;41:1563-1570.
    PubMed     Abstract available

    February 2021
  23. LEE HP, Tsai KW, Lee CC
    Prognostic Influence of Cytoplasmic/Nuclear Hepatoma-derived Growth Factor in Head and Neck Cancer.
    Anticancer Res. 2021;41:803-810.
    PubMed     Abstract available

  24. OSAWA M, Matsuda Y, Kinoshita Y, Wakai T, et al
    Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
    Anticancer Res. 2021;41:645-660.
    PubMed     Abstract available

  25. KABADI SM, Byfield SD, LE L, Olufade T, et al
    Adverse Events and Economic Burden Among Patients Receiving Systemic Treatment for Mantle Cell Lymphoma: A Real-World Retrospective Cohort Study.
    Anticancer Res. 2021;41:927-936.
    PubMed     Abstract available

    January 2021
  26. SAITO R, Amemiya H, Hosomura N, Kawaida H, et al
    Stroke Volume Variation Monitoring to Minimize Blood Loss in Hepatocellular Carcinoma Resection.
    Anticancer Res. 2021;41:409-415.
    PubMed     Abstract available

  27. AMEMIYA H, Matsuda M, Saito R, Hosomura N, et al
    Impact of Insulin Treatment on Prognosis of non-B non-C Hepatocellular Carcinoma After Hepatectomy.
    Anticancer Res. 2021;41:317-326.
    PubMed     Abstract available

  28. FABRITIUS MP, Hartmann F, Seidensticker R, Pech M, et al
    Liver Function Changes After Technetium-99m-Macroaggregated Albumin Administration and Their Predictive Value Regarding Hepatotoxicity in Patients Undergoing Yttrium-90-Radioembolization.
    Anticancer Res. 2021;41:437-444.
    PubMed     Abstract available

  29. KIM EJ, Kim M, Seo S, Kim MJ, et al
    Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin Versus Capecitabine/oxaliplatin.
    Anticancer Res. 2021;41:391-402.
    PubMed     Abstract available

    December 2020
  30. CHEN SY, Chao CN, Huang HY, Fang CY, et al
    Flavopereirine Inhibits Hepatocellular Carcinoma Cell Growth by Inducing Cell-cycle Arrest, Apoptosis, and Autophagy-related Protein Expression.
    Anticancer Res. 2020;40:6907-6914.
    PubMed     Abstract available

  31. LLUCH P, Segarra G, Tosca J, Navarro L, et al
    Oxidative and Nitrosative Pattern in Circulating Leukocytes of Very Early/Early Hepatocellular Carcinoma Patients.
    Anticancer Res. 2020;40:6853-6861.
    PubMed     Abstract available

  32. ABREU P, Ferreira R, Mineli V, Ribeiro MA, et al
    Alternative Biomarkers to Predict Tumor Biology in Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:6573-6784.
    PubMed     Abstract available

  33. SATO N, Yamamura K, Oda E, Akahoshi S, et al
    Cholangiolocarcinoma With Multiple Recurrences Successfully Treated With Repeated Liver Resection and Radiofrequency Ablation.
    Anticancer Res. 2020;40:7147-7153.
    PubMed     Abstract available

  34. YAMAMOTO J, Sugisawa N, Hamada K, Nishino H, et al
    A Universal Gelfoam 3-D Histoculture Method to Establish Patient-derived Cancer Cells (3D-PDCC) Without Fibroblasts from Patient-derived Xenografts.
    Anticancer Res. 2020;40:6765-6768.
    PubMed     Abstract available

  35. NAKAGAWA N, Tanaka K, Sonohara F, Kandimalla R, et al
    Novel Prognostic Implications of Methylated RNA and Demethylases in Resected HCC and Background Liver Tissue.
    Anticancer Res. 2020;40:6665-6676.
    PubMed     Abstract available

  36. PALEK R, Rosendorf J, Maleckova A, Vistejnova L, et al
    Influence of Mesenchymal Stem Cell Administration on The Outcome of Partial Liver Resection in a Porcine Model of Sinusoidal Obstruction Syndrome.
    Anticancer Res. 2020;40:6817-6833.
    PubMed     Abstract available

    November 2020
  37. YAMAMURA K, Beppu T, Kinoshita K, Oda E, et al
    Hepatocellular Carcinoma With Extensive Cancer-associated Thrombosis Successfully Treated With Liver Resection and Direct Oral Anticoagulant: A Case Report.
    Anticancer Res. 2020;40:6465-6471.
    PubMed     Abstract available

  38. DAHLQUIST KJV, Voth LC, Fee AJ, Stoeckman AK, et al
    An Autocrine Role for CXCL1 in Progression of Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:6075-6081.
    PubMed     Abstract available

  39. TOMIOKA K, Aoki T, Matsuda K, Fujimori A, et al
    Usefulness of a Transumbilical Incision for Organ Removal in Laparoscopic Hepatectomy.
    Anticancer Res. 2020;40:6545-6550.
    PubMed     Abstract available

  40. AHMED A, Halama N
    Tertiary Lymphoid Structures in Colorectal Cancer Liver Metastases: Association With Immunological and Clinical Parameters and Chemotherapy Response.
    Anticancer Res. 2020;40:6367-6373.
    PubMed     Abstract available

    October 2020
  41. YAMAMURA K, Beppu T, Sato N, Kinoshita K, et al
    Complete Removal of Adrenal Metastasis in Hepatocellular Carcinoma Using Indocyanine Green Fluorescent Imaging.
    Anticancer Res. 2020;40:5823-5828.
    PubMed     Abstract available

  42. SUGISAWA N, Nishino H, Higuchi T, Park JH, et al
    A Gemcitabine Plus 5-Fluorouracil Combination Inhibits Gastric-Cancer Liver Metastasis in a PDOX Model: A Novel Treatment Strategy.
    Anticancer Res. 2020;40:5393-5397.
    PubMed     Abstract available

    September 2020
  43. NARITA R, Kotoh K, Yoneda A, Motomura M, et al
    Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:5271-5276.
    PubMed     Abstract available

  44. GABATA R, Harada K, Mizutani Y, Ouchi H, et al
    Anti-tumor Activity of the Small Molecule Inhibitor PRI-724 Against beta-Catenin-activated Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:5211-5219.
    PubMed     Abstract available

  45. NAKURA M, Miyashita T, Yamamoto Y, Takada S, et al
    Inhibitory Effects of Beraprost Sodium in Murine Hepatic Sinusoidal Obstruction Syndrome.
    Anticancer Res. 2020;40:5171-5180.
    PubMed     Abstract available

  46. WU TK, Chen CH, Lee WT, Su TF, et al
    Cetyltrimethylammonium Bromide Suppresses the Migration and Invasion of Hepatic Mahlavu Cells by Modulating Fibroblast Growth Factor Signaling.
    Anticancer Res. 2020;40:5059-5069.
    PubMed     Abstract available

  47. OWADA S, Endo H, Okada C, Yoshida K, et al
    Setanaxib as a Potent Hypoxia-specific Therapeutic Agent Against Liver Cancer.
    Anticancer Res. 2020;40:5071-5079.
    PubMed     Abstract available

    August 2020
  48. GOTO Y, Hisaka T, Sakai H, Takagi K, et al
    Salvage Surgery for Initially Unresectable Locally Advanced Hepatocellular Carcinoma Downstaged by Hepatic Arterial Infusion Chemotherapy.
    Anticancer Res. 2020;40:4773-4777.
    PubMed     Abstract available

  49. KOJIMA S, Hisaka T, Midorikawa R, Naito Y, et al
    Prognostic Impact of Desmoplastic Reaction Evaluation for Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2020;40:4749-4754.
    PubMed     Abstract available

  50. HAN YH, Li WL, Jin MH, Jin YH, et al
    Peroxiredoxin II Inhibits Alcohol-induced Apoptosis in L02 Hepatocytes Through AKT/beta-Catenin Signaling Pathway.
    Anticancer Res. 2020;40:4491-4504.
    PubMed     Abstract available

  51. KWON JH, Yoo SH, Nam SW, Lee YJ, et al
    Diagnostic Role of Contrast-enhanced Ultrasound in the Discrimination of Malignant Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:4351-4363.
    PubMed     Abstract available

  52. HARIMOTO N, Araki K, Ishii N, Muranushi R, et al
    Predictors of Postoperative Ascites After Hepatic Resection in Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:4343-4349.
    PubMed     Abstract available

  53. HEINZE C, Omari J, Damm R, Hass P, et al
    Interstitial Brachytherapy for Limited (<4 cm) and Large (>/=4 cm) Hepatic Metastases from Rare and Less Common Cancers.
    Anticancer Res. 2020;40:4281-4289.
    PubMed     Abstract available

  54. YUE CH, Chen CH, Lee WT, Su TF, et al
    Cetyltrimethylammonium Bromide Disrupts the Mesenchymal Characteristics of HA22T/VGH Cells Via Inactivation of c-Met/PI3K/Akt/mTOR Pathway.
    Anticancer Res. 2020;40:4513-4522.
    PubMed     Abstract available

  55. HISAKA T, Sakai H, Sato T, Goto Y, et al
    Quercetin Suppresses Proliferation of Liver Cancer Cell Lines In Vitro.
    Anticancer Res. 2020;40:4695-4700.
    PubMed     Abstract available

    July 2020
  56. KIM HC, Joo I, Lee M, Kim YJ, et al
    Radioembolization-induced Tumor Calcifications as a Surrogate Marker of Tumor Response in Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:4191-4198.
    PubMed     Abstract available

  57. AMANUMA M, Nagai H, Igarashi Y
    Sorafenib Might Induce Sarcopenia in Patients With Hepatocellular Carcinoma by Inhibiting Carnitine Absorption.
    Anticancer Res. 2020;40:4173-4182.
    PubMed     Abstract available

  58. NAKAMURA M, Ueno M, Hayami S, Kawai M, et al
    Effective Response of Intrahepatic Cholangiocarcinoma to Pembrolizumab: A Case Report.
    Anticancer Res. 2020;40:4123-4129.
    PubMed     Abstract available

  59. SHIOGA T, Kondo R, Ogasawara S, Akiba J, et al
    Usefulness of Tumor Tissue Biopsy for Predicting the Biological Behavior of Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:4105-4113.
    PubMed     Abstract available

  60. SAKURAOKA Y, Kubota K, Tanaka G, Shimizu T, et al
    Features of Hepatocellular Carcinoma With Micro Hepatic Vein Invasion and their Correlation With Hepatitis B and C Virus.
    Anticancer Res. 2020;40:3983-3990.
    PubMed     Abstract available

  61. MORIGUCHI M, Aramaki T, Sato R, Iwai K, et al
    Intrahepatic Tumor Burden as a Novel Factor Influencing the Introduction of Second-line Chemotherapy for Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:3953-3960.
    PubMed     Abstract available

  62. IGUCHI T, Sugimachi K, Mano Y, Motomura T, et al
    Prognostic Impact of Geriatric Nutritional Risk Index in Patients With Synchronous Colorectal Liver Metastasis.
    Anticancer Res. 2020;40:4165-4171.
    PubMed     Abstract available

  63. TASHIRO Y, Aoki T, Hirai T, Koizumi T, et al
    Pathological Validity of Using Near-infrared Fluorescence Imaging for Securing Surgical Margins During Liver Resection.
    Anticancer Res. 2020;40:3873-3882.
    PubMed     Abstract available

  64. XIE DP, Gong YX, Jin YH, Ren CX, et al
    Anti-tumor Properties of Picrasma quassioides Extracts in H-Ras(G12V) Liver Cancer Are Mediated Through ROS-dependent Mitochondrial Dysfunction.
    Anticancer Res. 2020;40:3819-3830.
    PubMed     Abstract available

    June 2020
  65. MIYATA T, Takamura H, Kin R, Nishiki H, et al
    Spleen Volume as a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy.
    Anticancer Res. 2020;40:3361-3370.
    PubMed     Abstract available

  66. BAE KB, Kim SH, Kang MS, Kim DH, et al
    An Animal Model of Colorectal Cancer Liver Metastasis With a High Metastasis Rate and Clonal Dynamics.
    Anticancer Res. 2020;40:3297-3306.
    PubMed     Abstract available

    May 2020
  67. KAIDA T, Beppu T, Hayashi H, Imai K, et al
    Inflammatory Liver Tumor Caused by Fasciola hepatica Mimicking Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2020;40:2795-2800.
    PubMed     Abstract available

  68. LIM SC, Parajuli KR, Han SI
    Role of Death Receptors-associated Lipid Rafts in Oxaliplatin-induced Death Mode Regulation of HepG2 Cells.
    Anticancer Res. 2020;40:2573-2582.
    PubMed     Abstract available

    April 2020
  69. KUZUYA T, Ishigami M, Ito T, Ishizu Y, et al
    Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.
    Anticancer Res. 2020;40:2283-2290.
    PubMed     Abstract available

  70. LIU LI, Ahn E, Studeman K, Campbell K, et al
    Primary Hepatic Carcinosarcoma Composed of Hepatocellular Carcinoma, Cholangiocarcinoma, Osteosarcoma and Rhabdomyosarcoma With Poor Prognosis.
    Anticancer Res. 2020;40:2225-2229.
    PubMed     Abstract available

  71. KUZUYA T, Ishigami M, Ito T, Ishizu Y, et al
    Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2020;40:2089-2093.
    PubMed     Abstract available

  72. JELSKI W, Piechota J, Orywal K, Mroczko B, et al
    The Alterations in Alcohol Dehydrogenase Activity in the Sera of Women With Intrahepatic Cholestasis of Pregnancy.
    Anticancer Res. 2020;40:1997-2001.
    PubMed     Abstract available

  73. LEE J, Seo G, Hur W, Yoon SK, et al
    SRSF3 Depletion Leads to an Increase in SF3B4 Expression in SNU-368 HCC Cells.
    Anticancer Res. 2020;40:2033-2042.
    PubMed     Abstract available

    March 2020
  74. LAI HC, Chung WM, Chang CM, Liao PY, et al
    Androgen Receptor Enhances the Efficacy of Sorafenib Against Hepatocellular Carcinoma Through Enriched EpCAM Stemness.
    Anticancer Res. 2020;40:1285-1295.
    PubMed     Abstract available

  75. ZARLING L, Emamekhoo H, Bhutani G, Ziemlewicz T, et al
    Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report.
    Anticancer Res. 2020;40:1527-1534.
    PubMed     Abstract available

  76. PALKOVICS A, Vereczkei A, Fincsur A, Kiss I, et al
    Short- and Long-term Histological Changes in Liver Parenchyma After Different Resection Methods and Their Potential Role in Treatment of Colorectal Liver Metastasis.
    Anticancer Res. 2020;40:1359-1365.
    PubMed     Abstract available

    February 2020
  77. IWAHASI S, Rui F, Morine Y, Yamada S, et al
    Hepatic Stellate Cells Contribute to the Tumor Malignancy of Hepatocellular Carcinoma Through the IL-6 Pathway.
    Anticancer Res. 2020;40:743-749.
    PubMed     Abstract available

  78. YAMAMOTO K, Kuzuya T, Honda T, Ito T, et al
    Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib.
    Anticancer Res. 2020;40:665-676.
    PubMed     Abstract available

  79. NAKAMOTO T, Hokuto D, Nomi T, Yoshikawa T, et al
    Characteristics of Five-year Survivors After Liver Resection for Colorectal Liver Metastases in Modern Chemotherapy.
    Anticancer Res. 2020;40:1107-1116.
    PubMed     Abstract available

  80. ASSI HA, Mukherjee S, Machiorlatti M, Vesely S, et al
    Predictors of Outcome in Patients With Fibrolamellar Carcinoma: Analysis of the National Cancer Database.
    Anticancer Res. 2020;40:847-855.
    PubMed     Abstract available

    January 2020
  81. KARATAYLI E, Stokes CS, Lammert F
    Vitamin D in Preclinical Models of Fatty Liver Disease.
    Anticancer Res. 2020;40:527-534.
    PubMed     Abstract available

  82. SHIBA S, Shibuya K, Kawashima M, Okano N, et al
    Comparison of Dose Distributions When Using Carbon Ion Radiotherapy Versus Intensity-modulated Radiotherapy for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Retrospective Analysis.
    Anticancer Res. 2020;40:459-464.
    PubMed     Abstract available

  83. FEDER S, Kandulski A, Schacherer D, Weiss TS, et al
    Serum Adiponectin Levels Do Not Distinguish Primary from Metastatic Liver Tumors.
    Anticancer Res. 2020;40:143-151.
    PubMed     Abstract available

  84. DORR NM, Bartels M, Morgul MH
    Current Treatment of Colorectal Liver Metastasis as a Chronic Disease.
    Anticancer Res. 2020;40:1-7.
    PubMed     Abstract available

    December 2019
  85. SATO N, Beppu T, Kinoshita K, Yuki H, et al
    Partial Splenic Embolization for Lenvatinib Therapy-associated Thrombocytopenia Among Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:6895-6901.
    PubMed     Abstract available

  86. CHEN KH, Lai ZY, Li DY, Lin YC, et al
    Analysis of DNA Damage Responses After Boric Acid-mediated Boron Neutron Capture Therapy in Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:6661-6671.
    PubMed     Abstract available

  87. WAKANA H, Kono H, Fukushima H, Nakata Y, et al
    Effects of Medium-chain Triglycerides Administration in Chemically-induced Carcinogenesis in Mice.
    Anticancer Res. 2019;39:6653-6660.
    PubMed     Abstract available

    November 2019
  88. HORIUCHI T, Haruki K, Shiba H, Sakamoto T, et al
    Assessment of Outcome of Hepatic Resection for Extremely Elderly Patients With a Hepatic Malignancy.
    Anticancer Res. 2019;39:6325-6332.
    PubMed     Abstract available

  89. HO ML, Kuo WK, Chu LJ, Yeh IH, et al
    N-acetylgalactosamine-6-sulfatase (GALNS), Similar to Glycodelin, Is a Potential General Biomarker for Multiple Malignancies.
    Anticancer Res. 2019;39:6317-6324.
    PubMed     Abstract available

  90. OHTA S, Morine Y, Imura S, Ikemoto T, et al
    Carbohydrate Antigen 19-9 Is a Prognostic Factor Which Correlates With HDAC1 and HIF-1alpha for Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:6025-6033.
    PubMed     Abstract available

  91. OGASAWARA S, Mihara Y, Kondo R, Kusano H, et al
    Antiproliferative Effect of Lenvatinib on Human Liver Cancer Cell Lines In Vitro and In Vivo.
    Anticancer Res. 2019;39:5973-5982.
    PubMed     Abstract available

  92. ENDO M, Kanda M, Sawaki K, Shimizu D, et al
    Tissue Expression of Melanoma-associated Antigen A6 and Clinical Characteristics of Gastric Cancer.
    Anticancer Res. 2019;39:5903-5910.
    PubMed     Abstract available

    October 2019
  93. MARUKUCHI R, Furukawa K, Iwase R, Yasuda J, et al
    Risk Factors for Deterioration of Remnant Liver Function After Hepatic Resection for Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:5755-5760.
    PubMed     Abstract available

  94. SATO N, Beppu T, Kinoshita K, Yuki H, et al
    Conversion Hepatectomy for Huge Hepatocellular Carcinoma With Arterioportal Shunt After Chemoembolization and Lenvatinib Therapy.
    Anticancer Res. 2019;39:5695-5701.
    PubMed     Abstract available

  95. LIANG J, Ariizumi SI, Nakano M, Yamamoto M, et al
    Diabetes Mellitus and/or Nonalcoholic Steatohepatitis-related Hepatocellular Carcinoma Showed Favorable Surgical Outcomes After Hepatectomy.
    Anticancer Res. 2019;39:5639-5643.
    PubMed     Abstract available

  96. ZAIMOKU R, Miyashita T, Tajima H, Takamura H, et al
    Monitoring of Heat Shock Response and Phenotypic Changes in Hepatocellular Carcinoma After Heat Treatment.
    Anticancer Res. 2019;39:5393-5401.
    PubMed     Abstract available

  97. HUNG YH, Lin YC, Lin YT, Shih GW, et al
    Therapeutic Efficacy and Radiobiological Effects of Boric Acid-mediated BNCT in a VX2 Multifocal Liver Tumor-bearing Rabbit Model.
    Anticancer Res. 2019;39:5495-5504.
    PubMed     Abstract available

    September 2019
  98. TAKAHASHI A, Moriguchi M, Seko Y, Ishikawa H, et al
    Impact of Relative Dose Intensity of Early-phase Lenvatinib Treatment on Therapeutic Response in Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:5149-5156.
    PubMed     Abstract available

  99. HORIUCHI T, Haruki K, Shiba H, Sakamoto T, et al
    Assessment of Outcome of Hepatic Resection for Extremely Elderly Patients With a Hepatic Malignancy.
    Anticancer Res. 2019;39:5143-5148.
    PubMed     Abstract available

  100. AKAZAWA Y, Kono H, Hara M, Furuya S, et al
    M-CSF Receptor Antagonists Inhibit the Initiation and Progression of Hepatocellular Carcinoma in Mice.
    Anticancer Res. 2019;39:4787-4794.
    PubMed     Abstract available

  101. MORINE Y, Ikemoto T, Iwahashi S, Saito YU, et al
    Clinical Impact of FOLFOXIRI Aiming for Conversion Surgery in Unresectable Multiple Colorectal Liver Metastasis.
    Anticancer Res. 2019;39:5089-5096.
    PubMed     Abstract available

  102. SHIBUTANI M, Nagahara H, Fukuoka T, Iseki Y, et al
    Efficacy of Adjuvant Chemotherapy According to the Classification of Recurrence Risk Based on Systemic Inflammatory Markers in Patients With Liver Metastases of Colorectal Cancer.
    Anticancer Res. 2019;39:5039-5045.
    PubMed     Abstract available

  103. OSHIRO H, Tome Y, Kiyuna T, Yoon SN, et al
    Oral Recombinant Methioninase Overcomes Colorectal-cancer Liver Metastasis Resistance to the Combination of 5-Fluorouracil and Oxaliplatinum in a Patient-derived Orthotopic Xenograft Mouse Model.
    Anticancer Res. 2019;39:4667-4671.
    PubMed     Abstract available

    August 2019
  104. AMISAKI M, Yagyu T, Uchinaka EI, Morimoto M, et al
    Prognostic Value of DEPDC1 Expression in Tumor and Non-tumor Tissue of Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:4423-4430.
    PubMed     Abstract available

  105. SAKURAOKA Y, Kubota K, Imura J, Yamagishi H, et al
    Microsatellite Analysis of Recurrent Lesions Confirms Merit of Anatomical Liver Resection for Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:4315-4324.
    PubMed     Abstract available

  106. ARIIZUMI SI, Ban D, Abe Y, Kumamoto T, et al
    High-signal-intensity MR Image in the Hepatobiliary Phase Predicts Long-term Survival in Patients With Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:4219-4225.
    PubMed     Abstract available

  107. HISAKA T, Ishikawa H, Sakai H, Kawahara R, et al
    Sinusoidal Obstruction Syndrome and Postoperative Complications Resulting from Preoperative Chemotherapy for Colorectal Cancer Liver Metastasis.
    Anticancer Res. 2019;39:4549-4554.
    PubMed     Abstract available

  108. YOON SN, Park JH, Lwin TM, Miyake K, et al
    Tumor-sealing Surgical Orthotopic Implantation of Human Colon Cancer in Nude Mice Induces Clinically-relevant Metastases Without Early Peritoneal Carcinomatosis.
    Anticancer Res. 2019;39:4065-4071.
    PubMed     Abstract available

  109. SATAKE T, Suetsugu A, Nakamura M, Kunisada T, et al
    Color-coded Imaging of the Fate of Cancer-cell-derived Exosomes During Pancreatic Cancer Metastases in a Nude-mouse Model.
    Anticancer Res. 2019;39:4055-4060.
    PubMed     Abstract available

    July 2019
  110. SUNG PS, Yang K, Bae SH, Oh JS, et al
    Reduction of Intrahepatic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:3909-3916.
    PubMed     Abstract available

  111. WU TK, Chen CH, Pan YR, Hu CW, et al
    Cetrimonium Bromide Inhibits Cell Migration and Invasion of Human Hepatic SK-HEP-1 Cells Through Modulating the Canonical and Non-canonical TGF-beta Signaling Pathways.
    Anticancer Res. 2019;39:3621-3631.
    PubMed     Abstract available

  112. NAMGUNG Y, Kim SY, Kim I
    Down-regulation of Survivin by BIX-01294 Pretreatment Overcomes Resistance of Hepatocellular Carcinoma Cells to TRAIL.
    Anticancer Res. 2019;39:3571-3578.
    PubMed     Abstract available

  113. VUJIC J, Schollnast H, Marsoner K, Wienerroither V, et al
    Marking Disappearing Colorectal Liver Metastases After Complete Response to Neoadjuvant Chemotherapy via CT - A Pilot Study.
    Anticancer Res. 2019;39:3847-3854.
    PubMed     Abstract available

  114. CROWLEY E, Rowan NJ, Faller D, Friel AM, et al
    Natural and Synthetic Isothiocyanates Possess Anticancer Potential Against Liver and Prostate Cancer In Vitro.
    Anticancer Res. 2019;39:3469-3485.
    PubMed     Abstract available

    June 2019
  115. SAKATA K, Yoshizumi T, Izumi T, Shimokawa M, et al
    The Role of DNA Repair Glycosylase OGG1 in Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:3241-3248.
    PubMed     Abstract available

  116. SAITO R, Amemiya H, Hosomura N, Kawaida H, et al
    Prognostic Factors for Post-recurrent Survival in Hepatocellular Carcinoma After Curative Resection.
    Anticancer Res. 2019;39:3033-3038.
    PubMed     Abstract available

  117. LEE T, Park CK, Ha SY
    Prognostic Role of Apelin Receptor Expression in Hepatocellular Carcinoma Treated With Curative Surgical Resection.
    Anticancer Res. 2019;39:3025-3031.
    PubMed     Abstract available

  118. ZANG W, Bian H, Huang X, Yin G, et al
    Traditional Chinese Medicine (TCM) Astragalus Membranaceus and Curcuma Wenyujin Promote Vascular Normalization in Tumor-derived Endothelial Cells of Human Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:2739-2747.
    PubMed     Abstract available

  119. TAKAGI C, Kikuchi Y, Shirakawa H, Hoshimoto S, et al
    Predictive Factors for Elevated Postoperative Carbohydrate Antigen 19-9 Levels in Patients With Resected Pancreatic Cancer.
    Anticancer Res. 2019;39:3177-3183.
    PubMed     Abstract available

  120. MOKKARALA M, Noda C, Malone C, Ramaswamy R, et al
    Comparison of Response and Outcomes of Drug-eluting Bead Chemoembolization (DEB-TACE) Versus Radioembolization (TARE) for Patients With Colorectal Cancer Liver Metastases.
    Anticancer Res. 2019;39:3071-3077.
    PubMed     Abstract available

  121. ISHIKAWA D, Takasu C, Kashihara H, Nishi M, et al
    The Significance of MicroRNA-449a and Its Potential Target HDAC1 in Patients With Colorectal Cancer.
    Anticancer Res. 2019;39:2855-2860.
    PubMed     Abstract available

    May 2019
  122. NAKAO Y, Yamashita YI, Arima K, Miyata T, et al
    Clinical Usefulness of Perioperative C-reactive Protein/Albumin Ratio in Patients With Intrahepatic Cholangiocarcinoma: A Retrospective Single Institutional Study.
    Anticancer Res. 2019;39:2641-2646.
    PubMed     Abstract available

  123. OMARI J, Heinze C, Damm R, Hass P, et al
    Radioablation of Hepatic Metastases from Renal Cell Carcinoma With Image-guided Interstitial Brachytherapy.
    Anticancer Res. 2019;39:2501-2508.
    PubMed     Abstract available

  124. UNO S, Sakai M, Fujinari Y, Hosono T, et al
    Diallyl Trisulfide Enhances Benzo[a]pyrene-induced CYP1A1 Expression and Metabolic Activation in Hepatic HepG2 Cells.
    Anticancer Res. 2019;39:2369-2375.
    PubMed     Abstract available

  125. WENDLING-KEIM D, Vokuhl C, Walz C, Rieder L, et al
    Activation of Hedgehog Signaling in Aggressive Hepatic Hemangioma in Newborns and Infants.
    Anticancer Res. 2019;39:2351-2360.
    PubMed     Abstract available

    April 2019
  126. KIM SS, Eun JW, Cho HJ, Lee HY, et al
    Effect of Fibroblast Growth Factor-2 and its Receptor Gene Polymorphisms on the Survival of Patients With Hepatitis B Virus-associated Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:2217-2226.
    PubMed     Abstract available

  127. NAGAI H, Mukozu T, Kobayashi K, Amanuma M, et al
    Influence of Sorafenib on Host Immunity in Patients with Liver Cirrhosis With Advanced Hepatocellular Carcinoma Stratified by Etiology.
    Anticancer Res. 2019;39:2183-2191.
    PubMed     Abstract available

  128. MIYATA T, Beppu T, Imamura YU, Hayashi H, et al
    A 12-year Recurrence-free Survival After Multidisciplinary Treatment for a Patient With Combined Hepatocellular-Cholangiocarcinoma.
    Anticancer Res. 2019;39:2139-2144.
    PubMed     Abstract available

  129. YAMADA M, Yamamoto Y, Sugiura T, Kakuda Y, et al
    Comparison of the Clinicopathological Features in Small Bile Duct and Bile Ductular Type Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:2121-2127.
    PubMed     Abstract available

  130. ZHENG B, Yang S, Tian Q, Xie Y, et al
    Delivery of Antisense Oligonucleotide LOR-2501 Using Transferrin-conjugated Polyethylenimine-based Lipid Nanoparticle.
    Anticancer Res. 2019;39:1785-1793.
    PubMed     Abstract available

    March 2019

  131. Hepatic Stem Cells.
    Anticancer Res. 2019;39:1631.

  132. SCHNAPAUFF D, Tegel BR, Powerski MJ, Colletini F, et al
    Interstitial Brachytherapy in Combination With Previous Transarterial Embolization in Patients With Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2019;39:1329-1336.
    PubMed     Abstract available

  133. XU X, Gao D, Yuan X, Liu LI, et al
    beta-Catenin Expression Correlates With Prognosis in Hepatocellular Carcinoma Patients Treated With Transcatheter Arterial Chemoembolization.
    Anticancer Res. 2019;39:1129-1134.
    PubMed     Abstract available

  134. NISHIE A, Akahori S, Asayama Y, Ishigami K, et al
    Prediction of Liver Fibrosis Using CT Under Respiratory Control: New Attempt Using Deformation Vectors Obtained by Non-rigid Registration Technique.
    Anticancer Res. 2019;39:1417-1424.
    PubMed     Abstract available

  135. ORTEGA-GRANADOS AL, Artal-Cortes A, Aguiar-Bujanda D, Oramas J, et al
    Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer.
    Anticancer Res. 2019;39:1317-1328.
    PubMed     Abstract available

  136. YANO Y, Yoshimatsu K, Yokomizo H, Sagawa M, et al
    Enhancement of the Marginal Area in Colorectal Cancer Liver Metastasis on Computed Tomography Correlates With Microvessel Density and Clinicopathological Factors.
    Anticancer Res. 2019;39:1301-1308.
    PubMed     Abstract available

  137. KEMPER M, Strohm T, Grupp K, Ghadban T, et al
    Increase of CD45-positive Immune Cells in Liver Parenchyma Indicates a More Favorable Prognosis for Patients With Barrett's Cancer.
    Anticancer Res. 2019;39:1191-1196.
    PubMed     Abstract available

    February 2019
  138. HARIMOTO N, Hoshino K, Muranushi R, Hagiwara K, et al
    Impact of Metabolic Parameters of (18)F-Fluorodeoxyglucose Positron-emission Tomography After Hepatic Resection in Patients With Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:971-977.
    PubMed     Abstract available

  139. ARIMA K, Nitta H, Beppu T, Nakagawa S, et al
    Impact of Repeated Hepatectomy on Liver Regeneration in Hepatocellular Carcinoma: A Propensity Score-based Analysis.
    Anticancer Res. 2019;39:965-970.
    PubMed     Abstract available

  140. WATANABE A, Harimoto N, Araki K, Kubo N, et al
    Absolute Neutrophil Count Predicts Postoperative Prognosis in Mass-forming Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:941-947.
    PubMed     Abstract available

  141. YAMAO T, Yamashita YI, Imai K, Umezaki N, et al
    Clinical Significance of Preoperative Hepatocellular Carcinoma With High Lens culinaris Agglutinin-reactive Fraction of Alpha-Fetoprotein, But Low Alpha-Fetoprotein.
    Anticancer Res. 2019;39:883-889.
    PubMed     Abstract available

  142. CHEN JY, Huang WC, Wei CT, Chien PH, et al
    The C-Terminus of Hepatitis B Virus-encoded X Protein Is Required for Lapatinib Sensitivity in Hepatocellular Carcinoma Cells.
    Anticancer Res. 2019;39:721-726.
    PubMed     Abstract available

  143. WEI CT, Chen LC, Hsiang YP, Hung YJ, et al
    Chrysin-induced ERK1/2 Phosphorylation Enhances the Sensitivity of Human Hepatocellular Carcinoma Cells to Sorafenib.
    Anticancer Res. 2019;39:695-701.
    PubMed     Abstract available

  144. UMEZAKI N, Hashimoto D, Yamashita YI, Nakagawa S, et al
    Neuroendocrine Tumor of the Hilar Bile Duct.
    Anticancer Res. 2019;39:903-907.
    PubMed     Abstract available

    January 2019
  145. SEO S, Yoh T, Morino K, Fuji H, et al
    The Relationship Between (18)F-FDG Uptake on PET/CT and Markers of Systemic Inflammatory Response in Patients Undergoing Surgery for Intrahepatic Cholangiocarcinoma.
    Anticancer Res. 2019;39:341-346.
    PubMed     Abstract available

    December 2018
  146. MOCHIZUKI K, Kawai M, Odate T, Tahara I, et al
    SMARCB1/INI1 Is Diagnostically Useful in Distinguishing alpha-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:6865-6868.
    PubMed     Abstract available

  147. WU CY, Jan YJ, Ko BS, Wu YJ, et al
    Prognostic Significance of 14-3-3epsilon, Aldo-keto Reductase Family 1 B10 and Metallothionein-1 in Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:6855-6863.
    PubMed     Abstract available

  148. VALAKH V, Gresswell S, Kirichenko A
    Outcomes of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Severe Cirrhosis and Ineligibility for Transplant.
    Anticancer Res. 2018;38:6815-6820.
    PubMed     Abstract available

  149. WAKIYAMA H, Masuda T, Motomura Y, Hu Q, et al
    Cytolytic Activity (CYT) Score Is a Prognostic Biomarker Reflecting Host Immune Status in Hepatocellular Carcinoma (HCC).
    Anticancer Res. 2018;38:6631-6638.
    PubMed     Abstract available

    November 2018
  150. TOSHIMA T, Yoshizumi T, Ikegami T, Harada N, et al
    Impact of Osteopenia in Liver Cirrhosis: Special Reference to Standard Bone Mineral Density with Age.
    Anticancer Res. 2018;38:6465-6471.
    PubMed     Abstract available

  151. SO S, Komatsu S, Takebe A, Kido M, et al
    Novel Extracorporeal Hemoperfusion System for Hepatic Arterial Infusion of Cisplatin.
    Anticancer Res. 2018;38:6445-6452.
    PubMed     Abstract available

  152. XU J, Noda C, Erickson A, Mokkarala M, et al
    Radiofrequency Ablation vs. Cryoablation for Localized Hepatocellular Carcinoma: A Propensity-matched Population Study.
    Anticancer Res. 2018;38:6381-6386.
    PubMed     Abstract available

  153. MASUDA T, Margonis GA, Andreatos N, Wang J, et al
    Combined Hepatic Resection and Radio-frequency Ablation for Patients with Colorectal Cancer Liver Metastasis: A Viable Option for Patients with a Large Number of Tumors.
    Anticancer Res. 2018;38:6353-6360.
    PubMed     Abstract available

  154. MASUISHI T, Taniguchi H, Eto T, Komori A, et al
    Morphologic Response and Tumor Shrinkage as Early Predictive Markers in Unresectable Colorectal Liver Metastases.
    Anticancer Res. 2018;38:6501-6506.
    PubMed     Abstract available

  155. PALKOVICS A, Vereczkei A, Kalmar KN, Fincsur A, et al
    The Issue of Survival After Colorectal Liver Metastasis Surgery: Parenchyma Sparing vs. Radicality.
    Anticancer Res. 2018;38:6431-6438.
    PubMed     Abstract available

    October 2018
  156. THANGARAJAH F, Vogel C, Pahmeyer C, Eichler C, et al
    Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site.
    Anticancer Res. 2018;38:6023-6026.
    PubMed     Abstract available

  157. COLLOT T, Fumet JD, Klopfenstein Q, Vincent J, et al
    Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.
    Anticancer Res. 2018;38:5963-5968.
    PubMed     Abstract available

  158. TAKAMORI S, Takada K, Toyokawa G, Azuma K, et al
    PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:5897-5901.
    PubMed     Abstract available

  159. SUGIYAMA K, Narita Y, Mitani S, Honda K, et al
    Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.
    Anticancer Res. 2018;38:5859-5866.
    PubMed     Abstract available

    September 2018
  160. JIANG P, Gu L, Zhou Y, Zhao Y, et al
    Synchronous Laryngeal Squamous Cell Carcinoma and Intrahepatic Cholangiocarcinoma Present in an Obese Male with Poor Prognosis.
    Anticancer Res. 2018;38:5547-5550.
    PubMed     Abstract available

  161. SANO S, Yamamoto Y, Sugiura T, Okamura Y, et al
    The Radiological Differentiation of Hypervascular Intrahepatic Cholangiocarcinoma from Hepatocellular Carcinoma with a Focus on the CT Value on Multi-phase Enhanced CT.
    Anticancer Res. 2018;38:5505-5512.
    PubMed     Abstract available

  162. JORDAN F, Grundmann N, Schenkirsch G, Markl B, et al
    Impact of Primary Tumor Localization on the Efficacy of Bevacizumab in Metastatic Colorectal Cancer.
    Anticancer Res. 2018;38:5539-5546.
    PubMed     Abstract available

  163. TRESKA V, Fichtl J, Ludvik J, Bruha J, et al
    Portal Vein Embolization (PVE) Versus PVE with Haematopoietic Stem Cell Application in Patients with Primarily Non-resectable Colorectal Liver Metastases.
    Anticancer Res. 2018;38:5531-5537.
    PubMed     Abstract available

  164. HEINZE C, Omari J, Othmer M, Hass P, et al
    Image-guided Interstitial Brachytherapy in the Management of Metastasized Anal Squamous Cell Carcinoma.
    Anticancer Res. 2018;38:5401-5407.
    PubMed     Abstract available

  165. KAWAHARA H, Yoshida S, Tohyama Y, Yanagisawa S, et al
    Serum Carcinoembryonic Antigen Levels Before the First Curative Hepatectomy for Metastatic Colorectal Cancer Is a Predictor of Recurrence.
    Anticancer Res. 2018;38:5351-5355.
    PubMed     Abstract available

    August 2018
  166. HARIMOTO N, Hoshino H, Muranushi R, Hagiwara K, et al
    Skeletal Muscle Volume and Intramuscular Adipose Tissue Are Prognostic Predictors of Postoperative Complications After Hepatic Resection.
    Anticancer Res. 2018;38:4933-4939.
    PubMed     Abstract available

  167. YU JI, Choi GS, Lim DH, Lee E, et al
    Treatment of Naive HCC Combined with Segmental or Subsegmental Portal Vein Tumor Thrombosis: Liver Resection Versus TACE Followed by Radiotherapy.
    Anticancer Res. 2018;38:4919-4925.
    PubMed     Abstract available

  168. ROSSI L, Biagioni C, McCartney A, Moretti E, et al
    Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.
    Anticancer Res. 2018;38:4839-4845.
    PubMed     Abstract available

  169. MORIMOTO M, Honjo S, Sakamoto T, Uchinaka EI, et al
    Pilot Study of Probe-based Confocal Laser Endomicroscopy with Fluorescein-dripping Method for Liver Tumors.
    Anticancer Res. 2018;38:4775-4781.
    PubMed     Abstract available

  170. SHIROYAMA T, Suzuki H, Tamiya M, Tamiya A, et al
    Clinical Characteristics of Liver Metastasis in Nivolumab-treated Patients with Non-small Cell Lung Cancer.
    Anticancer Res. 2018;38:4723-4729.
    PubMed     Abstract available

    July 2018
  171. UCHIYAMA H, Komatsu KI, Nakata A, Sato K, et al
    Global Liver Gene Expression Analysis on a Murine Hepatic Steatosis Model Treated with Mulberry (Morus alba L.) Leaf Powder.
    Anticancer Res. 2018;38:4305-4311.
    PubMed     Abstract available

  172. NOH CK, Wang HJ, Kim CM, Kim J, et al
    EpCAM as a Predictive Marker of Tumor Recurrence and Survival in Patients Who Underwent Surgical Resection for Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:4101-4109.
    PubMed     Abstract available

  173. KOGA Y, Beppu T, Miyata T, Kitano Y, et al
    Predicting Poorly Differentiated Hepatocellular Carcinoma that Meets the Milan Criteria.
    Anticancer Res. 2018;38:4093-4099.
    PubMed     Abstract available

  174. SCHMIDT TM, Liu LI, Abraham IE, Uy AB, et al
    Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:4027-4034.
    PubMed     Abstract available

  175. TSAI TJ, Chao WY, Chen CC, Chen YJ, et al
    Gelsolin-like Actin-capping Protein (CapG) Overexpression in the Cytoplasm of Human Hepatocellular Carcinoma, Associated with Cellular Invasion, Migration and Tumor Prognosis.
    Anticancer Res. 2018;38:3943-3950.
    PubMed     Abstract available

  176. INAGAWA H, Saika T, Nishiyama N, Nisizawa T, et al
    Dewaxed Brown Rice Feed Improves Fatty Liver in Obese and Diabetic Model Mice.
    Anticancer Res. 2018;38:4339-4345.
    PubMed     Abstract available

  177. JELSKI W, Wolszczak-Biedrzycka B, Zasimowicz-Majewska E, Orywal K, et al
    Alcohol Dehydrogenase Isoenzymes and Aldehyde Dehydrogenase Activity in the Serum of Patients with Non-alcoholic Fatty Liver Disease.
    Anticancer Res. 2018;38:4005-4009.
    PubMed     Abstract available

  178. MIRKA H, Duras P, Baxa J, Korcakova E, et al
    Contribution of Computed Tomographic Angiography to Pretreatment Planning of Radio-embolization of Liver Tumors.
    Anticancer Res. 2018;38:3825-3829.
    PubMed     Abstract available

    June 2018
  179. SHIBA S, Shibuya K, Katoh H, Koyama Y, et al
    No Deterioration in Clinical Outcomes of Carbon Ion Radiotherapy for Sarcopenia Patients with Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:3579-3586.
    PubMed     Abstract available

  180. ANDO K, Sakoda M, Ueno S, Hiwatashi K, et al
    Clinical Implication of the Relationship Between High Mobility Group Box-1 and Tumor Differentiation in Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:3411-3418.
    PubMed     Abstract available

  181. SAWAZAKI S, Numata M, Morita J, Maezawa Y, et al
    Safety of Laparoscopic Surgery for Colorectal Cancer in Patients with Severe Comorbidities.
    Anticancer Res. 2018;38:3767-3772.
    PubMed     Abstract available

  182. TRESKA V, Topolcan O, Zoubkova V, Treskova I, et al
    Perioperative Tumour Marker Levels as Prognostic Factors for Surgical Treatment of Breast Cancer Liver Metastases.
    Anticancer Res. 2018;38:3647-3652.
    PubMed     Abstract available

    May 2018
  183. MACHAIRAS N, Papaconstantinou D, Stamopoulos P, Prodromidou A, et al
    The Emerging Role of Laparoscopic Liver Resection in the Treatment of Recurrent Hepatocellular Carcinoma: A Systematic Review.
    Anticancer Res. 2018;38:3181-3186.
    PubMed     Abstract available

  184. YOSHIDA M, Beppu T, Shiraishi S, Tsuda N, et al
    Liver Function in Areas of Hepatic Venous Congestion After Hepatectomy for Liver Cancer: (99m)Tc-GSA SPECT/CT Fused Imaging Study.
    Anticancer Res. 2018;38:3089-3095.
    PubMed     Abstract available

  185. IWABU J, Namikawa T, Tsuda S, Kitagawa H, et al
    Successful Distal Gastrectomy for Gastric Cancer with Child-Pugh Class B Alcoholic Liver Cirrhosis.
    Anticancer Res. 2018;38:3085-3087.
    PubMed     Abstract available

  186. LAI JZ, Zhou Y, Cao D
    Synchronous Pancreatic Ductal Adenocarcinoma and Hepatocellular Carcinoma: Report of a Case and Review of the Literature.
    Anticancer Res. 2018;38:3009-3012.
    PubMed     Abstract available

  187. SHIH YL, Huang YH, Lin KH, Chu YD, et al
    Identification of Functional Thyroid Stimulating Hormone Receptor and TSHR Gene Mutations in Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:2793-2802.
    PubMed     Abstract available

  188. HABERL EM, Pohl R, Rein-Fischboeck L, Feder S, et al
    Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
    Anticancer Res. 2018;38:2649-2657.
    PubMed     Abstract available

  189. ALFONSO PG, Podesta MC, Martin AM, Codeisido MB, et al
    Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases.
    Anticancer Res. 2018;38:3069-3077.
    PubMed     Abstract available

  190. CHANG J, Charalel R, Noda C, Ramaswamy R, et al
    Liver-dominant Breast Cancer Metastasis: A Comparative Outcomes Study of Chemoembolization Versus Radioembolization.
    Anticancer Res. 2018;38:3063-3068.
    PubMed     Abstract available

  191. DESHWAR A, Margonis GA, Andreatos N, Barbon C, et al
    Double KRAS and BRAF Mutations in Surgically Treated Colorectal Cancer Liver Metastases: An International, Multi-institutional Case Series.
    Anticancer Res. 2018;38:2891-2895.
    PubMed     Abstract available

  192. NASSEREDDINE S, Alsubait S, Tabbara I
    Sinusoidal Obstruction Syndrome (Veno-occlusive Disease) Following Hematopoietic Stem Cell Transplant: Insights and Therapeutic Advances.
    Anticancer Res. 2018;38:2597-2605.
    PubMed     Abstract available

    April 2018
  193. KANG WH, Tak E, Hwang S, Song GW, et al
    Metformin-associated Chemopreventive Effects on Recurrence After Hepatic Resection of Hepatocellular Carcinoma: From In Vitro to a Clinical Study.
    Anticancer Res. 2018;38:2399-2407.
    PubMed     Abstract available

  194. TSAI JJ, Hsu FT, Pan PJ, Chen CW, et al
    Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma In Vivo.
    Anticancer Res. 2018;38:2119-2125.
    PubMed     Abstract available

  195. SATAKE T, Suetsugu A, Nakamura M, Hasegawa K, et al
    Differential Organ-targeting and Cellular Characteristics of Metastatic Human Pancreatic Cancer Cell Lines in Mouse Models.
    Anticancer Res. 2018;38:1927-1935.
    PubMed     Abstract available

    March 2018
  196. TOYA R, Saito T, Shiraishi S, Kai Y, et al
    Dose-function Histogram Evaluation Using (99m)Tc-GSA SPECT/CT Images for Stereotactic Body Radiation Therapy Planning for Hepatocellular Carcinoma Patients: A Dosimetric Parameter Comparison.
    Anticancer Res. 2018;38:1511-1516.
    PubMed     Abstract available

  197. OKANO N, Kasuga A, Kawai K, Yamauchi Y, et al
    The Modified Glasgow Prognostic Score in Patients with Gemcitabine-refractory Biliary Tract Cancer.
    Anticancer Res. 2018;38:1755-1761.
    PubMed     Abstract available

  198. FILIPESCU A, Balescu I, Bacalbasa N
    Upper Abdominal Resection for Isolated Metastatic Lesions in Recurrent Cervical Cancer.
    Anticancer Res. 2018;38:1659-1663.
    PubMed     Abstract available

  199. KINOSHITA K, Beppu T, Miyata T, Kuramoto K, et al
    A Case of 15-Year Recurrence-free Survival After Microwave Coagulation Therapy for Liver Metastasis from Gastric Cancer.
    Anticancer Res. 2018;38:1595-1598.
    PubMed     Abstract available

  200. MORIS D, Ntanasis-Stathopoulos I, Tsilimigras DI, Vagios S, et al
    Update on Surgical Management of Small Bowel Neuroendocrine Tumors.
    Anticancer Res. 2018;38:1267-1278.
    PubMed     Abstract available

    February 2018
  201. IMAI K, Yamashita YI, Yusa T, Nakao Y, et al
    Microvascular Invasion in Small-sized Hepatocellular Carcinoma: Significance for Outcomes Following Hepatectomy and Radiofrequency Ablation.
    Anticancer Res. 2018;38:1053-1060.
    PubMed     Abstract available

  202. TSUKAMOTO M, Yamashita YI, Imai K, Umezaki N, et al
    Long-term Favorable Outcomes of Radiofrequency Ablation for Hepatocellular Carcinoma as an Initial Treatment: A Single-center Experience Over a 10-Year Period.
    Anticancer Res. 2018;38:1047-1052.
    PubMed     Abstract available

  203. SATTLER T, Bredt C, Surwald S, Rust C, et al
    Efficacy and Safety of Drug Eluting Bead TACE with Microspheres <150 mum for the Treatment of Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:1025-1032.
    PubMed     Abstract available

  204. UEMOTO K, Doi H, Shiomi H, Yamada K, et al
    Clinical Assessment of Micro-residual Tumors during Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
    Anticancer Res. 2018;38:945-954.
    PubMed     Abstract available

  205. HORTON CE, Kamal M, Leslie M, Zhang R, et al
    Circulating Tumor Cells Accurately Predicting Progressive Disease After Treatment in a Patient with Non-small Cell Lung Cancer Showing Response on Scans.
    Anticancer Res. 2018;38:1073-1076.
    PubMed     Abstract available

  206. OSADA S, Gotoh A, Yokoi R, Tsuchiya H, et al
    Effective Timing of Surgical Resection of Colorectal Cancer Liver Metastases During Chemotherapy.
    Anticancer Res. 2018;38:737-743.
    PubMed     Abstract available

  207. DOI H, Beppu N, Kitajima K, Kuribayashi K, et al
    Stereotactic Body Radiation Therapy for Liver Tumors: Current Status and Perspectives.
    Anticancer Res. 2018;38:591-599.
    PubMed     Abstract available

  208. CEAUSU AR, Ciolofan A, Cimpean AM, Magheti A, et al
    The Mesenchymal-Epithelial and Epithelial-Mesenchymal Cellular Plasticity of Liver Metastases with Digestive Origin.
    Anticancer Res. 2018;38:811-816.
    PubMed     Abstract available

    January 2018
  209. KURAMOTO K, Beppu T, Nitta H, Imai K, et al
    Hepatic Resection Followed by Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Intrahepatic Dissemination.
    Anticancer Res. 2018;38:525-531.
    PubMed     Abstract available

  210. YOSHIMOTO T, Imura S, Morine Y, Ikemoto T, et al
    The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
    Anticancer Res. 2018;38:501-507.
    PubMed     Abstract available

  211. SPELT L, Sasor A, Ansari D, Hilmersson KS, et al
    The Prognostic Role of Cancer Stem Cell Markers for Long-term Outcome After Resection of Colonic Liver Metastases.
    Anticancer Res. 2018;38:313-320.
    PubMed     Abstract available

  212. VIRGILIO E, Cavallini M
    Managing Focal Nodular Hyperplasia of the Liver: Surgery or Minimally-invasive Approaches? A Review of the Preferable Treatment Options.
    Anticancer Res. 2018;38:33-36.
    PubMed     Abstract available

    December 2017
  213. TSUKAMOTO M, Yamashita YI, Imai K, Umezaki N, et al
    Predictors of Cure of Intrahepatic Cholangiocarcinoma After Hepatic Resection.
    Anticancer Res. 2017;37:6971-6975.
    PubMed     Abstract available

  214. LIANG YH, Shao YY, Chen HM, Cheng AL, et al
    Irinotecan and Oxaliplatin Might Provide Equal Benefit as Adjuvant Chemotherapy for Patients with Resectable Synchronous Colon Cancer and Liver-confined Metastases: A Nationwide Database Study.
    Anticancer Res. 2017;37:7095-7104.
    PubMed     Abstract available

  215. MIYATA T, Beppu T, Higashi T, Nakagawa S, et al
    A Glissonean Approach with Individual Isolation During Right Hemi-Hepatectomy After Portal Vein Embolization.
    Anticancer Res. 2017;37:7069-7071.
    PubMed     Abstract available

  216. SHIBATA H, Ohike N, Norose T, Isobe T, et al
    Mucinous Cystic Neoplasms Lined by Abundant Mucinous Epithelium Frequently Involve KRAS Mutations and Malignant Progression.
    Anticancer Res. 2017;37:7063-7068.
    PubMed     Abstract available

  217. CAIVANO D, Valeriani M, Russo I, Bonome P, et al
    Stereotactic Body Radiation Therapy in Primary and Metastatic Liver Disease.
    Anticancer Res. 2017;37:7005-7010.
    PubMed     Abstract available

    November 2017
  218. BAI YC, Hsia YC, Lin YT, Chen KH, et al
    Effect of Tumor Microenvironment on Selective Uptake of Boric Acid in HepG2 Human Hepatoma Cells.
    Anticancer Res. 2017;37:6347-6353.
    PubMed     Abstract available

  219. CIRIMBEI C, Rotaru V, Chitoran E, Pavaleanu O, et al
    Immediate and Long-term Results of Radiofrequency Ablation for Colorectal Liver Metastases.
    Anticancer Res. 2017;37:6489-6494.
    PubMed     Abstract available

  220. SATONAKA H, Ishida K, Takai M, Koide R, et al
    (-)-Epigallocatechin-3-gallate Down-regulates Doxorubicin-induced Overexpression of P-glycoprotein Through the Coordinate Inhibition of PI3K/Akt and MEK/ERK Signaling Pathways.
    Anticancer Res. 2017;37:6071-6077.
    PubMed     Abstract available

    October 2017
  221. IMURA S, Yamada S, Saito YU, Iwahashi S, et al
    miR-223 and Stathmin-1 Expression in Non-tumor Liver Tissue of Patients with Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:5877-5883.
    PubMed     Abstract available

  222. MORINE Y, Imura S, Ikemoto T, Iwahashi S, et al
    CD44 Expression Is a Prognostic Factor in Patients with Intrahepatic Cholangiocarcinoma After Surgical Resection.
    Anticancer Res. 2017;37:5701-5705.
    PubMed     Abstract available

  223. RATHMANN N, Kara K, Budjan J, Henzler T, et al
    Parenchymal Liver Blood Volume and Dynamic Volume Perfusion CT Measurements of Hepatocellular Carcinoma in Patients Undergoing Transarterial Chemoembolization.
    Anticancer Res. 2017;37:5681-5685.
    PubMed     Abstract available

  224. IKEMOTO T, Shimada M, Ishikawa D, Kawashita Y, et al
    Peripheral Tr1 and Foxp3+ Treg as Markers of Recurrent Malignancies in Patients with Hepato-Biliary Pancreatic Cancers.
    Anticancer Res. 2017;37:5541-5552.
    PubMed     Abstract available

  225. KISHIMOTO S, Yasuda M, Fukushima S
    Changes in the Expression of Various Transporters as Influencing Factors of Resistance to Cisplatin.
    Anticancer Res. 2017;37:5477-5484.
    PubMed     Abstract available

    September 2017
  226. SAKABE T, Azumi J, Umekita Y, Toriguchi K, et al
    Expression of Cancer Stem Cell-associated DKK1 mRNA Serves as Prognostic Marker for Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:4881-4888.
    PubMed     Abstract available

  227. BI YE, Zhou Y, Wang M, Li L, et al
    Targeted Delivery of Cordycepin to Liver Cancer Cells Using Transferrin-conjugated Liposomes.
    Anticancer Res. 2017;37:5207-5214.
    PubMed     Abstract available

  228. CICERO G, Lo Re G, DE Luca R, Vernuccio F, et al
    Role of Densitometric Criteria in Evaluation of Effectiveness of Antiangiogenic Therapies in Metastatic Colorectal Cancer: An Italian Clinical Experience.
    Anticancer Res. 2017;37:5187-5192.
    PubMed     Abstract available

  229. DIVELLA R, Daniele A, DE Luca R, Simone M, et al
    Circulating Levels of VEGF and CXCL1 Are Predictive of Metastatic Organotropismin in Patients with Colorectal Cancer.
    Anticancer Res. 2017;37:4867-4871.
    PubMed     Abstract available

    August 2017
  230. WANG L, Liu M, Liu L, Zheng Y, et al
    MR-guided Percutaneous Biopsy of Focal Hepatic Dome Lesions with Free-hand Combined with MR Fluoroscopy Using 1.0-T Open High-field Scanner.
    Anticancer Res. 2017;37:4635-4641.
    PubMed     Abstract available

  231. GONG Z, Chi C, Huang X, Chu H, et al
    Cyclophilin A Is Overexpressed in Hepatocellular Carcinoma and Is Associated with the Cell Cycle.
    Anticancer Res. 2017;37:4443-4447.
    PubMed     Abstract available

  232. ZHANG WG, Yin XC, Liu XF, Meng KW, et al
    Puerarin Induces Hepatocellular Carcinoma Cell Apoptosis Modulated by MAPK Signaling Pathways in a Dose-dependent Manner.
    Anticancer Res. 2017;37:4425-4431.
    PubMed     Abstract available

    July 2017
  233. HARADA N, Yoshizumi T, Yamashita YI, Soejima Y, et al
    Impact and Prediction of Lymph Node Involvement in Patients with Intrahepatic Cholangiocarcinoma After Curative Resection.
    Anticancer Res. 2017;37:3763-3769.
    PubMed     Abstract available

  234. KRAUTBAUER S, Weiss TS, Wiest R, Schacherer D, et al
    Diagnostic Value of Systemic Cholesteryl Ester/Free Cholesterol Ratio in Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3527-3535.
    PubMed     Abstract available

  235. HAYASHI T, Yamashita T, Okada H, Oishi N, et al
    A Novel mTOR Inhibitor; Anthracimycin for the Treatment of Human Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3397-3403.
    PubMed     Abstract available

  236. ISHII F, Yoshida Y, Yamauchi Y, Aisu N, et al
    Hepatectomy for Liver Metastases of Colorectal Cancer After Adoptive Chemoimmunotherapy Using Activated alphabeta T-cells.
    Anticancer Res. 2017;37:3933-3939.
    PubMed     Abstract available

  237. SHIBA I, Kouzaki R, Yamada H, Endo Y, et al
    Design and Synthesis of Novel Anti-metastatic Hypoxic Cytotoxin TX-2137 Targeting AKT Kinase.
    Anticancer Res. 2017;37:3877-3883.
    PubMed     Abstract available

  238. SETO K, Sakabe T, Itaba N, Azumi J, et al
    A Novel Small-molecule WNT Inhibitor, IC-2, Has the Potential to Suppress Liver Cancer Stem Cells.
    Anticancer Res. 2017;37:3569-3579.
    PubMed     Abstract available

  239. NAKAMURA M, Suetsugu A, Hasegawa K, Matsumoto T, et al
    Choline-Deficient-Diet-Induced Fatty Liver Is a Metastasis-Resistant Microenvironment.
    Anticancer Res. 2017;37:3429-3434.
    PubMed     Abstract available

    June 2017
  240. WAKIYAMA S, Matsumoto M, Haruki K, Gocho T, et al
    Clinical Features and Outcome of Surgical Patients with Non-B Non-C Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3207-3213.
    PubMed     Abstract available

  241. MATSUMOTO T, Ichikawa H, Imai J, Hayashi T, et al
    Feasibility and Safety of Repeated Transarterial Chemoembolization Using Miriplatin-Lipiodol Suspension for Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:3183-3187.
    PubMed     Abstract available

  242. LIN CL, Chien RN, Liang KH, Ke PY, et al
    Intrahepatic HCV RNA Level and Genotype 1 Independently Associate with Hepatic Reticulon 3 Expression.
    Anticancer Res. 2017;37:2885-2891.
    PubMed     Abstract available

    May 2017
  243. MIYATA T, Yamashita YI, Yamao T, Umezaki N, et al
    Clinical Benefits of Lymph Node Dissection in Intrahepatic Cholangiocarcinoma: A Retrospective Single-institution Study.
    Anticancer Res. 2017;37:2673-2677.
    PubMed     Abstract available

  244. HASHIMOTO M, Kobayashi T, Ishiyama K, Ide K, et al
    Predictive Independent Factors for Extrahepatic Metastasis of Hepatocellular Carcinoma Following Curative Hepatectomy.
    Anticancer Res. 2017;37:2625-2631.
    PubMed     Abstract available

  245. LU LC, Chen PJ, Yeh YC, Hsu CH, et al
    Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
    Anticancer Res. 2017;37:2593-2599.
    PubMed     Abstract available

  246. KANAJI N, Kita N, Kadowaki N, Bandoh S, et al
    Fibronectin and Hepatocyte Growth Factor Produced by Lung Fibroblasts Augment Migration and Invasion of Malignant Pleural Mesothelioma Cells.
    Anticancer Res. 2017;37:2393-2400.
    PubMed     Abstract available

  247. BARABINO M, Gatti A, Santambrogio R, Polizzi M, et al
    Intraoperative Local Ablative Therapies Combined with Surgery for the Treatment of Bilobar Colorectal Liver Metastases.
    Anticancer Res. 2017;37:2743-2750.
    PubMed     Abstract available

    April 2017
  248. MALKI A, El-Sharkawy A, El Syaed M, Bergmeier S, et al
    Antitumor Activities of the Novel Isosteviol Derivative 10C Against Liver Cancer.
    Anticancer Res. 2017;37:1591-1601.
    PubMed     Abstract available

  249. TAHARA T, Tahara S, Horiguchi N, Kawamura T, et al
    Telomere Length in Leukocyte DNA in Gastric Cancer Patients and its Association with Clinicopathological Features and Prognosis.
    Anticancer Res. 2017;37:1997-2001.
    PubMed     Abstract available

  250. OTTAIANO A, Capozzi M, DE Divitiis C, VON Arx C, et al
    Nab-Paclitaxel and Gemcitabine in Advanced Pancreatic Cancer: The One-year Experience of the National Cancer Institute of Naples.
    Anticancer Res. 2017;37:1975-1978.
    PubMed     Abstract available

  251. HARADA N, Yoshizumi T, Maeda T, Kayashima H, et al
    Preoperative Pancreatic Stiffness by Real-time Tissue Elastography to Predict Pancreatic Fistula After Pancreaticoduodenectomy.
    Anticancer Res. 2017;37:1909-1915.
    PubMed     Abstract available

    March 2017
  252. DE PASQUALE MD, de Ville de Goyet J, Monti L, Grimaldi C, et al
    Bevacizumab Combined with Chemotherapy in Children Affected by Hepatocellular Carcinoma: a Single-center Experience.
    Anticancer Res. 2017;37:1489-1493.
    PubMed     Abstract available

  253. ITOH S, Uchiyama H, Ikeda Y, Morita K, et al
    Post-hepatectomy Refractory Ascites in Cirrhotic Patients with Hepatocellular Carcinoma: Risk Factor Analysis to Overcome this Problematic Complication.
    Anticancer Res. 2017;37:1381-1385.
    PubMed     Abstract available

  254. MARQUES LA, Semprebon SC, Sartori D, DE Fatima A, et al
    Comparison of the Effects of Monastrol and Oxomonastrol on Human Hepatoma Cell Line HepG2/C3A.
    Anticancer Res. 2017;37:1197-1204.
    PubMed     Abstract available

  255. YOSHIKAWA M, Morine Y, Ikemoto T, Imura S, et al
    Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial-Mesenchymal Transition.
    Anticancer Res. 2017;37:1169-1175.
    PubMed     Abstract available

  256. KOMATSU H, Masuda T, Iguchi T, Nambara S, et al
    Clinical Significance of FANCD2 Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma.
    Anticancer Res. 2017;37:1083-1090.
    PubMed     Abstract available

  257. TRESKA V, Fichtl J, Bruha J, Liska V, et al
    Liver Resections for Colorectal Metastases in Patients Aged Over 75 Years.
    Anticancer Res. 2017;37:1529-1533.
    PubMed     Abstract available

  258. D'ONOFRIO M, Cingarlini S, Ortolani S, Crosara S, et al
    Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment.
    Anticancer Res. 2017;37:1305-1311.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.